Despite great interest in the elevated circulating levels of calcitriol (1,25[O-12D) associated with the clinical syndrome of human primary hyperparathyroidism, the relative potencies of known and potential stimuli/suppressors of long-term calcitriol levels have not been evaluated in either clinical or experimentally induced hyperparathyroid states. Based on reports that aparathyroid animals exhibit suppressed plasma calcitriol concentration and that acute administration of parathyroid hormone (PTH) to both humans and experimental animals or to renal slices in vitro results in increased plasma calcitriol concentration/production rate, it might be predicted that a chronic experimental model of either hypercalcemic primary hyperparathyroidism or hypocalcemic secondary hyperparathyroidism would show increased plasma calcitriol concentration. Chronic alterations in plasma calcium concentration have not been implicated as modulating calcitriol levels in any species. Accordingly, we investigated the long-term response of plasma calcitriol concentration in states of sustained experimental primary and secondary hyperparathyroidism. Intact dogs (group I) undergoing continuous intravenous PTH infusion for 12 d developed sustained hypercalcemia and hypophosphatemia, and plasma calcitriol concentration decreased from 23±3 to 14±3 pg/ml (P < 0.01). Subsequent chelator (EGTA)-induced chronic normalization of hypercalcemia during ongoing PTH infusion resulted in a large and sustained increase in plasma calcitriol concentration to supernormal levels, reversible during subsequent cessation of chelator infusion. In additional intact dogs (group II), chronic chelator-induced hypocalcemic secondary hyperparathyroidism resulted in a sustained increase in plasma calcitriol concentration despite hyperphosphatemia. In normal human subjects undergoing a 12-13-d continuous intravenous PTH infusion to result in sustained moderate hypercalcemia (12.0±0.2 mg/100 ml) and hypophosphatemia, plasma calcitriol concentration decreased significantly (P < 0.01) as in group I dogs and was followed by reversal to normal levels in a recovery period. The present results provide strong evidence in both humans and dogs that during experimentally induced chronic PTH 
Introduction
A wide variety of experimental evidence in both humans and laboratory animals indicates that the renal mitochondrial metabolite, calcitriol, is the most potent known circulating metabolite of vitamin D and that physiological variation in plasma calcitriol concentration can account, in large part, for the known effects of vitamin D on mineral metabolism in bone, intestine, and extracellular fluid (ECF) (1, 2) . However, the identities and relative potencies of the individual factors that regulate the steady-state plasma concentration of calcitriol are still unclear. Postulated stimuli for calcitriol production include chronic dietary calcium restriction (3) (4) (5) (6) (7) (8) , acute administration of parathyroid hormone (PTH) (8) (9) (10) (11) , and chronic hypophosphatemia (4, (12) (13) (14) (15) . Recently, it has been reported that in calves and goats, acute hypercalcemia, per se, can suppress plasma calcitriol concentration despite the continued presence of high circulating PTH levels (16) .
Clinical states of chronically deranged calcium metabolism typically provide a difficult setting for interpretation of plasma calcitriol concentration inasmuch as clinical circumstances often dictate potentially conflicting signals to calcitriol production (e.g., PTH excess vs. hypercalcemia in primary hyperparathyroidism). Studies investigating the chronic steady-state regulation of plasma calcitriol concentration in response to prolonged, independent (and potentially conflicting signal) alterations in plasma calcium, PTH, and phosphorus concentrations have not been reported in any species.
To investigate the chronic regulation of plasma calcitriol concentration, we have assessed the relative potency of potential conflicting signals by performing experiments in dogs and humans in which plasma calcium concentration is maintained, at chronically increased or decreased levels in the presence of either increased or absent PTH levels and with control of plasma phosphate concentration. The results of these studies indicate that as long as minimal (albeit suppressed) PTH is present in both dogs and humans, the long-term magnitude of plasma calcium concentration, over a wide range of values, is a more potent regulator of plasma calcitriol concentration than is PTH.
Methods

Studies in dogs
The chronic effects of PTH-excess and calcium-excess states on plasma and urinary mineral composition and vitamin D metabolism were determined in 12 female mongrel dogs weighing [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] kg. Throughout the studies the dogs were fed a constant amount (30 calcium and phosphorus concentrations were achieved. After completion of control period observations, synthetic b-(l-34)-PTH 6,800 U/mg (Beckman Instruments, Inc., Fullerton, CA), was added to the infusate at a rate of 6 U/kg per 24 h for a period of 12-13 d. The infusion rate was occasionally decreased when plasma calcium concentration exceeded 13 mg/100 ml for >24 h. A 4-8-d recovery period followed the period of PTH administration in which PTH was removed from the infusate.
Analytical procedures
All determinations were performed in duplicate. Analytical methods used in this laboratory have been described in previous reports (17, 18) . Plasma calcidiol (25-hydroxyvitamin D3) and calcitriol concentrations were measured as reported previously (21), with the exception that in the studies in humans, the calcitriol fraction from LH-20 chromatography was further chromatographed using a radial compression separation system (Waters Instruments, Inc., Rochester, MN) with an 8-mm Si radial compression column (particle size, 5 Mm), a solvent system of isopropanol/hexane (8:92), and a flow rate of 4.5 ml/min.
Overall recoveries of initial tritiated calcidiol and calcitriol added to the plasma were 60-65 and 60-70%, respectively. Minimum assay detection limits for calcidiol and calcitriol are -5 ng/ml and 4 pg/ml, respectively. Intraassay and interassay coefficients of variation for calcidiol (plasma concentration, 28 ng/ml) are -10 and 15%, respectively, and for calcitriol (plasma concentration, 31 pg/ml) are 12 and 13%, respectively. Plasma and urine calcium concentrations were determined by automated fluorometric titration (22) , which measures nonchelated total calcium. Statistical analysis is by t test (23) .
Results
Group I: effect of chronic intravenous infusion of bPTH on mineral and vitamin D metabolism in intact dogs. Chronic continuous administration of bPTH resulted in sustained hypercalcemia and hypophosphatemia (Fig. 1) . No significant alterations in body weight or plasma protein concentration were observed. Plasma calcitriol concentration decreased from a stable control period value of 23±3 to 14±3 pg/ml (P < 0.05) ( Table I) .
In a single animal of group I, subsequent Na4 EGTAinduced normalization of PTH-induced hypercalcemia and hypophosphatemia resulted in an increase in plasma calcitriol level to approximately twice that observed in the control period. Subsequent substitution of CaNa2 EGTA (nonchelator) resulted in recurrence of hypercalcemia and resuppression of calcitriol concentration (Fig. 2) (Fig. 3) . Group III. effect of chronic hypercalcemia induced by the substitution of continuous intravenously administered calcium chloridefor equivalent sodium chloride to TPTX dogs. Sustained infusion of calcium resulted in an increase in plasma calcium concentration from a chronic subnormal level to a sustained supernormal level (Table I, Fig. 4) . Plasma phosphorus and calcitriol concentrations were not altered substantially.
Group IV: effect of chronic hypercalcemic hyperparathyroidism induced by continuous PTH infusion in normal human subjects. Sustained infusion of bPTH (1-34) resulted in persistent hypercalcemia, hypophosphatemia, and decreased plasma calcitriol concentrations (Fig. 5) . These results in human subjects were qualitatively similar to those in the normal dogs of group I. Plasma calcidiol concentration averaged 31±4 ng/ml during the control period and was not significantly different during days 7-13 of PTH administration (30±2 ng/ ml). The ranges of normal human calcidiol and calcitriol concentrations in our laboratory are 15-60 ng/ml and 15-60 pg/ml, respectively.
Discussion
Several lines of evidence might lead one to predict that the stimulatory effect of PTH on renal calcitriol production would result in a chronic increase in plasma calcitriol concentration in normal dogs and humans when experimentally induced PTH excess is permitted to persist into a steady-state period of secondary hypercalcemia and hypophosphatemia. First, the common clinical syndrome, primary hyperparathyroidism, is characterized by stable hypercalcemia, hypophosphatemia, and elevated plasma calcitriol concentration (12, (24) (25) (26) (27) . If persistent hypersecretion of PTH were the exclusive cause of the clinical syndrome, then elevated plasma calcitriol concentration should also obtain when PTH excess is of exogenous experimental origin. Second, hypoparathyroid rats exhibit deficient calcitriol production, which has been reported to be corrected by acute PTH administration, suggesting that PTH provides tonic stimulation of calcitriol levels (3, 9) . Third, normal human subjects have been reported to respond with increased plasma calcitriol concentration after acute administration of large doses of PTH (7, 28). Fourth, direct addition of PTH to incubated rat renal slices resulted in large increases in calcitriol production (29).
Fifth, direct addition of PTH to a renal mitochondrial preparation resulted in a dose-dependent increase in activity of the enzyme responsible for calcitriol production, 25-hydroxyvitamin D-1 a-hydroxylase (1 a-hydroxylase) (10 in models of primary PTH excess (high PTH, hypophosphatemia; groups I and IV) and increased calcitriol concentration in a model of secondary PTH excess (high PTH, hyperphosphatemia; group II). The occurrence of hyperphosphatemia despite augmented renal phosphate clearance in the group with secondary hyperparathyroidism (group II) is of interest inasmuch as an augmentation of renal phosphate clearance also accompanied the development of hypercalcemic hypophosphatemic hyperparathyroidism (groups I and IV). The observation that urinary phosphate excretion remained persistently and greatly elevated above control levels during the steady state of EGTA-induced hypocalcemia is consistent with the thesis that gastrointestinal phosphate absorption increased (or failed to decrease) only in animals with secondary PTH excess owing to increased circulating calcitriol levels (1). The cumulative increment in phosphate excretion of 9.6 mmol/kg in group II hypocalcemic dogs is markedly greater than the values of 0 mmol/kg and 1.7 mmol/kg in groups I and IV hypercalcemic dogs and humans (Table I) . Taken together with the finding that the cumulative increment in urinary calcium excretion followed a similar pattern (11.0 meq/kg, group II vs. 1.0 and 0.6 meq/kg in groups I and IV), the occurrence of persistent hyperphosphatemia and hyperphosphaturia in dogs with secondary hyperparathyroidism supports the possibility that augmented calcitriol levels in this condition (but not in models of primary PTH excess) resulted in a large increase in the systemic loads of both calcium and phosphate requiring renal excretion. Since the equimolar EGTA salts infused in both control and experimental periods (group II) obligate identical calcium loads requiring renal excretion, the large increment in urinary calcium excretion is not attributable to chelator infusion, per se. Since both the models of primary PTH excess and secondary PTH excess employed herein would be expected to exhibit large losses of bone calcium and phosphate to ECF, the striking differences between primary and secondary models with respect to the observed magnitude of sustained urinary calcium and phosphate losses, suggest a calcitriol-mediated alteration in gastrointestinal absorption of both ions (1) .
The potential role of chronic changes in plasma calcium concentration in determining the direction and magnitude of the response of plasma calcitriol concentration to sustained PTH excess requires consideration. It is established that chronic oral calcium loading in humans results in decreased plasma calcitriol concentration and that chronic calcium restriction results in increased plasma calcitriol concentration (5) . However, these results have been interpreted as suggesting an effect of secondarily decreased or increased PTH levels rather than direct effects of small but undetectable changes in plasma calcium concentration. More recently, however, Trechsel et al. (3) have shown in rats that chronic calcium restriction resulted in increased plasma calcitriol concentration even in TPTX rats or rats with a fixed PTH supply as well as in control rats. The operation of plasma calcium concentration as the dominant mechanism in calcitriol metabolism was not established by these studies, however, since as in the human studies, differences in plasma calcium concentration were not demonstrable consistently in response to the dietary maneuver. In studies reported by Hughes et al. (4) , however, TPTX rats were provided a calcium-restricted diet for a longer period of time (2 wk) (8) .
The results of studies evaluating the specific (PTH-independent) role of acute changes in ECF calcium concentration on calcitriol production utilizing isolated chick renal tubules bathed in a Krebs-Ringer solution are consistent with an effect of hypercalcemia to decrease calcitriol production but inconsistent with an effect of hypocalcemia to stimulate calcitriol production (30) . The studies in incubated tubules revealed a biphasic response of calcitriol production to increasing ambient calcium concentration. At subphysiologic levels (<0.5 mM), calcitriol production was inhibited, whereas at normal or superphysiological levels (>1.0 mM), increasing calcium concentration also inhibited production relative to maximal rates observed in the 0.5-1.0 mM range (30) . A preliminary report using incubated rat renal slices has confirmed that an increase in medium calcium concentration from 0.5 to 1.25 mM resulted in decreased calcitriol production (31) . Numerous investigations of the effects of incubation medium calcium concentration on renal mitochondrial calcitriol production have been reported. A comprehensive and critical review of these reports has been published (2), which points out the methodological difficulties encumbering interpretation of the conflicting results. Based on current information it is difficult to predict whether changes in ECF calcium concentration might modulate mitochondrial calcitriol production through direct effects on cytosolic calcium concentration or through unknown mechanisms. (16) in two goats receiving a constant superphysiological infusion rate of PTH, showed that superimposed hypercalcemia resulting from a brief calcium infusion was associated with a decreased plasma calcitriol concentration. The reason(s) for the opposite results of acute PTH administration to humans (increased calcitriol concentration; 7, 28) were not elucidated by these investigations. The potential role of plasma calcium-mediated modulation of calcitonin metabolism in mediating the present changes in calcitriol metabolism as well as the acute changes reported by Hove et al. remains to be determined (32, 33) .
The finding of the present studies that sustained hypercal-cemia induced in aparathyroid dogs (group III) resulted in only a minimal trend toward a reduction in plasma calcitriol concentration, raises the possibility that plasma calcium concentration modulates circulating calcitriol levels only in the presence of PTH. Alternatively, since the hypercalcemic calcitriol levels in this group (5 pg/ml) are at the detection limit of current assay techniques (4 pg/ml), it might be argued that PTH-independent suppression of plasma calcitriol concentration would be unlikely to be detected when basal levels are near the detection limit (7 pg/ml) owing to the aparathyroid state.
The present results provide strong evidence in both humans and dogs that during experimental states of chronic PTH excess, alterations in plasma calcium concentration dictate the directional response of plasma calcitriol concentration. These studies further indicate that the long-term potency of plasma calcium concentration as a regulator of plasma calcitriol concentration is sufficient to override opposing modulation by plasma phosphorus concentration and experimentally induced hyperparathyroidism in both dogs and humans. The reason(s) for the important differences in the present findings from those of primary hyperparathyroidism were not elucidated by the present studies. Further investigations into the proximate cause of the clinical syndrome (e.g., hypersecretion of additional hormones) as well as investigation of more prolonged experimental models than those reported herein will be of great value in approaching this question.
